ICL Stock Analysis: ICL Israel Chemicals | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 6.415m USD | 12M Return: -18.9% | IL0002810146 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.03M
EPS Trend: -78.0%
Qual. Beats: 1
Rev. Trend: -10.6%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICL Group Ltd is a specialty minerals and chemicals company headquartered in Tel Aviv-Yafo, Israel, operating through four segments: Industrial Products, Potash, Phosphate Solutions, and Growing Solutions. The Industrial Products segment leverages bromine, a by-product of potash production, to manufacture bromine-based compounds, flame retardants, and phosphorus-based products, while also selling potash, salt, and magnesia products. The Potash segment produces and markets potash, salt, magnesium, electricity, magnesium alloys, chlorine, and sylvinite. The Phosphate Solutions segment transforms phosphate commodity products into specialty items such as fertilizers, phosphoric acid, phosphate salts, and functional food ingredients. The Growing Solutions segment focuses on specialty fertilizers, including water-soluble and controlled-release products, as well as bio-stimulants, soil conditioners, seed treatments, and digital agronomy platforms.
The company serves a diverse range of industries, including pharmaceutical, food, oil and gas, de-icing, building and construction, oral care, paints and coatings, energy storage, water treatment, electronics, automotive, agriculture, textiles, tire manufacturing, and healthcare, as well as power plants and battery producers. It distributes its products through marketing companies, agents, and distributors. Originally incorporated in 1968 as Israel Chemicals Ltd., the company rebranded as ICL Group Ltd in May 2020 and trades on the NYSE as a mid-cap stock in the Materials sector, specifically within the Fertilizers & Agricultural Chemicals sub-industry. As a major player in the global potash and phosphate markets, ICL benefits from the essential role these nutrients play in agricultural productivity, while its specialty chemicals business adds higher-margin exposure to industrial applications.
- Potash prices swing on global fertilizer demand and supply
- Bromine demand rises from battery and flame retardant markets
- Phosphate specialty margins pressured by energy and sulfur costs
| Net Income: 305.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.33 > 1.0 |
| NWC/Revenue: 21.52% < 20% (prev 26.02%; Δ -4.49% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.08b > Net Income 305.0m |
| Net Debt (2.89b) to EBITDA (1.46b): 1.98 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago -0.11% < -2% |
| Gross Margin: 30.63% > 18% (prev 32.29%; Δ -1.66% > 0.5%) |
| Asset Turnover: 60.34% > 50% (prev 56.19%; Δ 4.15% > 0%) |
| Interest Coverage Ratio: 2.47 > 6 (EBIT TTM 818.0m / Interest Expense TTM 331.0m) |
| A: 0.13 (Total Current Assets 4.50b - Total Current Liabilities 2.84b) / Total Assets 13.2b |
| B: 0.45 (Retained Earnings 5.90b / Total Assets 13.2b) |
| C: 0.06 (EBIT TTM 818.0m / Avg Total Assets 12.8b) |
| D: 0.91 (Book Value of Equity 6.15b / Total Liabilities 6.75b) |
| Altman-Z'' = 3.67 = AA |
| DSRI: 1.03 (Receivables 1.64b/1.43b, Revenue 7.71b/6.95b) |
| GMI: 1.05 (GM 32.29% / 30.63%) |
| AQI: 1.02 (AQ_t 0.12 / AQ_t-1 0.12) |
| SGI: 1.11 (Revenue 7.71b / 6.95b) |
| TATA: -0.06 (NI 305.0m - CFO 1.08b) / TA 13.2b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of October 21, 2026, the stock is trading at USD 4.88 with a total of 1,745,985 shares traded. Over the past week, the price has changed by -1.21%, over one month by -8.61%, over three months by -1.41% and over the past year by -18.94%.
Current recommended Stop Loss: 4.70 (which is 3.7% or 1.6 ATR below the current price).
ICL Israel Chemicals has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold ICL.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.7 | 17.6% |
P/E Trailing = 20.7083
P/E Forward = 55.5556
P/S = 0.8318
P/B = 1.1131
P/EG = 9.44
Revenue TTM = 7.71b USD
EBIT TTM = 818.0m USD
EBITDA TTM = 1.46b USD
Long Term Debt = 2.65b USD (from longTermDebt, last quarter)
Short Term Debt = 646.0m USD (from shortTermDebt, last quarter)
Debt = 3.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 255.0m
Net Debt = 2.89b USD (calculated: Debt 3.55b - CCE 662.0m)
Enterprise Value = 9.30b USD (6.41b + Debt 3.55b - CCE 662.0m)
Interest Coverage Ratio = 2.47 (Ebit TTM 818.0m / Interest Expense TTM 331.0m)
EV/FCF = 31.98x (Enterprise Value 9.30b / FCF TTM 291.0m)
FCF Yield = 3.13% (FCF TTM 291.0m / Enterprise Value 9.30b)
FCF Margin = 3.77% (FCF TTM 291.0m / Revenue TTM 7.71b)
Net Margin = 3.95% (Net Income TTM 305.0m / Revenue TTM 7.71b)
Gross Margin = 30.63% ((Revenue TTM 7.71b - Cost of Revenue TTM 5.35b) / Revenue TTM)
Gross Margin QoQ = 31.10% (prev 30.94%)
Tobins Q-Ratio = 0.71 (Enterprise Value 9.30b / Total Assets 13.2b)
Interest Expense / Debt = 9.32% (Interest Expense 331.0m / Debt 3.55b)
Taxrate = 33.95% (184.0m / 542.0m)
NOPAT = 540.3m (EBIT 818.0m * (1 - 33.95%))
Current Ratio = 1.58 (Total Current Assets 4.50b / Total Current Liabilities 2.84b)
Debt / Equity = 0.58 (Debt 3.55b / totalStockholderEquity, last quarter 6.15b)
Debt / EBITDA = 1.98 (Net Debt 2.89b / EBITDA 1.46b)
Debt / FCF = 9.93 (Net Debt 2.89b / FCF TTM 291.0m)
Total Stockholder Equity = 6.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.39% (Net Income 305.0m / Total Assets 13.2b)
RoE = 5.02% (Net Income TTM 305.0m / Total Stockholder Equity 6.08b)
RoCE = 9.37% (EBIT 818.0m / Capital Employed (Equity 6.08b + L.T.Debt 2.65b))
RoIC = 5.09% (NOPAT 540.3m / Invested Capital 10.6b)
WACC = 7.09% (E(6.41b)/V(9.97b) * Re(7.60%) + D(3.55b)/V(9.97b) * Rd(9.32%) * (1-Tc(0.34)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 48.03 | Cagr: 0.01%
[DCF] Terminal Value 73.10% ; FCFF base≈349.7m ; Y1≈306.7m ; Y5≈247.8m
[DCF] Fair Price = 0.84 (EV 3.98b - Net Debt 2.89b = Equity 1.09b / Shares 1.29b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -78.05 | EPS CAGR: -26.44% | SUE: 0.84 | # QB: 1
Revenue Correlation: -10.60 | Revenue CAGR: -0.56% | SUE: 2.10 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.10 | Chg30d=-8.71% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=0.41 | Chg30d=-3.05% | Revisions=+17% | GrowthEPS=+13.1% | GrowthRev=+11.4%
EPS next Year (2027-12-31): EPS=0.43 | Chg30d=-1.32% | Revisions=-17% | GrowthEPS=+6.8% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -10% (up=3, down=4)